| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | Patients with all KIR ligands present (n=13) had a significantly higher (p=0.04) incidence of acute graft-versus-host-disease (GVHD) than patients with one or more KIR ligands missing (n=37). | 27394130 | 2016 | ||||
|
0.080 | Biomarker | disease | BEFREE | Patients with acute myeloid leukemia (AML, n = 612) lacking ≥ 1 KIR ligands experienced higher grade III to IV acute graft-versus-host disease (GVHD) (HR, 1.6; 95% CI, 1.16 to 2.28; P = .005) compared to those with all ligands present. | 25960307 | 2015 | ||||
|
0.080 | Biomarker | disease | BEFREE | KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation. | 19169284 | 2009 | ||||
|
0.080 | Biomarker | disease | BEFREE | The "KIR receptor-receptor" and the "KIR receptor-ligand" models seemed the most capable of predicting NK alloreactivity because they had a significant impact on acute graft-versus-host disease (aGVHD) occurrence, OS, and relapse incidence in D/R unrelated pairs. | 19822295 | 2009 | ||||
|
0.080 | Biomarker | disease | BEFREE | KIR and KIR2DL1 mismatch is associated with lower aGVHD in Chinese after HLA-identical sibling hematopoietic stem cell transplantation. | 18347914 | 2008 | ||||
|
0.080 | Biomarker | disease | BEFREE | The KIR ligand-ligand mismatch model is a good predictor of acute graft vs. host disease (aGVHD; HR 3.812, 95% CI 1.667-8.720, P = 0.002). | 17378893 | 2007 | ||||
|
0.080 | Biomarker | disease | BEFREE | These results suggest that the number of KIR genes in donors could influence the occurrence of acute GVHD after unrelated HSCT. | 17445182 | 2007 | ||||
|
0.080 | Biomarker | disease | BEFREE | We investigated the influence of killer cell immunoglobulin-like receptor (KIR) genes, based on the genotypes of inhibitory or activating KIR, in stem cell recipients with acute myelogenous leukemia and their human leukocyte antigen-matched sibling donors on acute graft-versus host disease (GVHD) after hematopoietic stem cell transplantation. | 17998861 | 2007 |